Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies.
AKI follow-up
Acute kidney injury (AKI)
biomarker
end-stage kidney disease (ESKD)
heart failure
hospitalization
kidney disease progression
mortality
prognosis
risk stratification
sTNFR2
soluble tumor necrosis factor receptor 1 (sTNFR1)
Journal
American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
21
02
2022
accepted:
04
08
2022
pmc-release:
01
02
2024
pubmed:
16
9
2022
medline:
25
1
2023
entrez:
15
9
2022
Statut:
ppublish
Résumé
The role of plasma soluble tumor necrosis factor receptor 1 (sTNFR1) and sTNFR2 in the prognosis of clinical events after hospitalization with or without acute kidney injury (AKI) is unknown. Prospective cohort. Hospital survivors from the ASSESS-AKI (Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury) and ARID (AKI Risk in Derby) studies with and without AKI during the index hospitalization who had baseline serum samples for biomarker measurements. We measured sTNFR1 and sTNFR2 from plasma samples obtained 3 months after discharge. The associations of biomarkers with longitudinal kidney disease incidence and progression, heart failure, and death were evaluated. Cox proportional hazard models. Among 1,474 participants with plasma biomarker measurements, 19% had kidney disease progression, 14% had later heart failure, and 21% died during a median follow-up of 4.4 years. For the kidney outcome, the adjusted HRs (AHRs) per doubling in concentration were 2.9 (95% CI, 2.2-3.9) for sTNFR1 and 1.9 (95% CI, 1.5-2.5) for sTNFR2. AKI during the index hospitalization did not modify the association between biomarkers and kidney events. For heart failure, the AHRs per doubling in concentration were 1.9 (95% CI, 1.4-2.5) for sTNFR1 and 1.5 (95% CI, 1.2-2.0) for sTNFR2. For mortality, the AHRs were 3.3 (95% CI, 2.5-4.3) for sTNFR1 and 2.5 (95% CI, 2.0-3.1) for sTNFR2. The findings in ARID were qualitatively similar in terms of the magnitude of association between biomarkers and outcomes. Different biomarker platforms and AKI definitions; limited generalizability to other ethnic groups. Plasma sTNFR1 and sTNFR2 measured 3 months after hospital discharge were independently associated with clinical events regardless of AKI status during the index admission. sTNFR1 and sTNFR2 may assist with the risk stratification of patients during follow-up.
Identifiants
pubmed: 36108888
pii: S0272-6386(22)00871-X
doi: 10.1053/j.ajkd.2022.08.007
pmc: PMC9868060
mid: NIHMS1835929
pii:
doi:
Substances chimiques
Receptors, Tumor Necrosis Factor
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
190-200Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK115562
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK116967
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK126477
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079310
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK106962
Pays : United States
Organisme : NIDDK NIH HHS
ID : UH3 DK114920
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL085757
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK090203
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK117065
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK112258
Pays : United States
Organisme : NIDDK NIH HHS
ID : L30 DK081985
Pays : United States
Informations de copyright
Copyright © 2022 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Références
J Intensive Care. 2014 May 07;2(1):31
pubmed: 25520843
PLoS One. 2013;8(2):e55477
pubmed: 23405158
Curr Opin Crit Care. 2006 Dec;12(6):544-50
pubmed: 17077684
Kidney Int. 2009 Nov;76(10):1089-97
pubmed: 19741590
Am J Kidney Dis. 2016 May;67(5):742-52
pubmed: 26690912
Sci Rep. 2020 Sep 9;10(1):14852
pubmed: 32908199
Adv Chronic Kidney Dis. 2016 May;23(3):186-94
pubmed: 27113695
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):200-209
pubmed: 27577245
Clin Nephrol. 2019 Jul;92(1):15-24
pubmed: 30990413
Kidney Int. 2010 Nov;78(9):926-33
pubmed: 20686452
Adv Chronic Kidney Dis. 2017 Jul;24(4):246-252
pubmed: 28778365
Circulation. 2009 Mar 17;119(10):1355-7
pubmed: 19255338
J Am Geriatr Soc. 2018 Apr;66(4):804-811
pubmed: 29360163
Am J Kidney Dis. 2020 Feb;75(2):204-213
pubmed: 31537394
BMJ Open. 2017 Mar 29;7(3):e015316
pubmed: 28360257
N Engl J Med. 2020 Jun 4;382(23):2238-2247
pubmed: 32492305
Nephron. 2015;131(2):102-6
pubmed: 26340262
PLoS One. 2015 Mar 30;10(3):e0122073
pubmed: 25823004
J Am Soc Nephrol. 2016 Mar;27(3):687-97
pubmed: 26519085
Diabetes Metab Res Rev. 2019 Nov;35(8):e3195
pubmed: 31207020
J Cardiothorac Vasc Anesth. 2015;29(3):617-25
pubmed: 25575408
Clin J Am Soc Nephrol. 2012 Apr;7(4):533-40
pubmed: 22362062
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1015-23
pubmed: 24742481
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
Am J Kidney Dis. 2022 May;79(5):646-656.e1
pubmed: 34653541
Kidney Int. 2012 Mar;81(5):442-8
pubmed: 22113526
BMC Nephrol. 2018 Apr 19;19(1):91
pubmed: 29673338
Sci Rep. 2019 Nov 18;9(1):16963
pubmed: 31740699
Glob Heart. 2013 Mar 1;8(1):77-82
pubmed: 23998000
Kidney Int. 2019 Jan;95(1):160-172
pubmed: 30473140
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Soc Nephrol. 2018 Nov;29(11):2713-2721
pubmed: 30287518
Sci Rep. 2020 Apr 16;10(1):6490
pubmed: 32300140
J Am Heart Assoc. 2018 Apr 23;7(9):
pubmed: 29686027
Medicine (Baltimore). 2017 May;96(19):e6666
pubmed: 28489742
Am J Kidney Dis. 2016 Mar;67(3 Suppl 1):Svii, S1-305
pubmed: 26925525
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):926-33
pubmed: 25862777
Clin J Am Soc Nephrol. 2014 Mar;9(3):448-56
pubmed: 24311708
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
Sci Rep. 2020 Nov 17;10(1):20005
pubmed: 33203963
JAMA Netw Open. 2020 Oct 1;3(10):e2019209
pubmed: 33021646
J Am Soc Nephrol. 2009 Jan;20(1):223-8
pubmed: 19020007
BMC Nephrol. 2010 Aug 27;11:22
pubmed: 20799966
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
Am J Kidney Dis. 2011 Aug;58(2):206-13
pubmed: 21496979
Am J Respir Crit Care Med. 2017 Mar 15;195(6):784-791
pubmed: 27635668